The results of joint research with Professor Handa and Associate Professor Ito of Tokyo Medical University were published in the open access journal Communications Biology on November 11. This is the finding that pomalidomide, a small molecule compound used as a treatment for multiple myeloma, causes selective degradation of the disease-related protein PLZF, suggesting that PLZF may be applicable to the treatment of leukemia and other diseases in which PLZF is involved in pathogenesis.